AZN vs. EXAS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AZN and EXAS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN dominates in value with a market cap of 432.07 billion USD, eclipsing EXAS’s 10.73 billion USD by roughly 40.26×.
EXAS carries a higher beta at 0.92, indicating it’s more sensitive to market moves, while AZN remains steadier at 0.18.
AZN trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while EXAS remains a standard domestic listing.
| Symbol | AZN | EXAS |
|---|---|---|
| Company Name | AstraZeneca PLC | Exact Sciences Corporation |
| Country | GB | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Diagnostics & Research |
| CEO | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Mr. Kevin T. Conroy J.D. |
| Price | 69.68 USD | 56.89 USD |
| Market Cap | 432.07 billion USD | 10.73 billion USD |
| Beta | 0.18 | 0.92 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 12, 1993 | February 1, 2001 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of AZN and EXAS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of AZN and EXAS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- EXAS shows a negative P/E of -10.42, highlighting a year of losses, whereas AZN at 27.80 trades on solid profitability.
- EXAS shows a negative forward PEG of -9.67, signaling expected earnings contraction, while AZN at 2.50 maintains analysts’ projections for stable or improved profits.
| Symbol | AZN | EXAS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.80 | -10.42 |
| Forward PEG Ratio (TTM) | 2.50 | -9.67 |
| Price-to-Sales Ratio (P/S, TTM) | 3.93 | 3.79 |
| Price-to-Book Ratio (P/B, TTM) | 5.26 | 4.43 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.33 | 55.28 |
| EV-to-EBITDA (TTM) | 13.68 | -15.21 |
| EV-to-Sales (TTM) | 4.41 | 4.56 |
| EV-to-Free Cash Flow (TTM) | 25.07 | 66.48 |
Dividend Comparison
AZN delivers a 1.39% dividend yield, blending income with growth, whereas EXAS appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | AZN | EXAS |
|---|---|---|
| Dividend Yield (TTM) | 1.39% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AZN and EXAS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 signals a possible liquidity squeeze, while EXAS at 2.73 comfortably covers its short-term obligations.
- AZN’s quick ratio of 0.70 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas EXAS at 2.38 maintains a comfortable buffer of liquid assets.
- AZN meets its interest obligations (ratio 7.95). In stark contrast, EXAS’s negative ratio (-57.46) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
| Symbol | AZN | EXAS |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 2.73 |
| Quick Ratio (TTM) | 0.70 | 2.38 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 1.05 |
| Debt-to-Assets Ratio (TTM) | 0.30 | 0.44 |
| Interest Coverage Ratio (TTM) | 7.95 | -57.46 |